HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nalin Rastogi Selected Research

Tuberculosis (Tuberculoses)

6/2023Insight into pathogenomics and phylogeography of hypervirulent and highly-lethal Mycobacterium tuberculosis strain cluster.
1/2019Clonal expansion across the seas as seen through CPLP-TB database: A joint effort in cataloguing Mycobacterium tuberculosis genetic diversity in Portuguese-speaking countries.
1/2019Insights on the Mycobacterium tuberculosis population structure associated with migrants from Portuguese-speaking countries over a three-year period in Greater Lisbon, Portugal: Implications at the public health level.
12/2016New Mycobacterium tuberculosis LAM sublineage with geographical specificity for the Old World revealed by phylogenetical and Bayesian analyses.
12/2015Multidrug-Resistant Mycobacterium tuberculosis of the Latin American Mediterranean Lineage, Wrongly Identified as Mycobacterium pinnipedii (Spoligotype International Type 863 [SIT863]), Causing Active Tuberculosis in South Brazil.
1/2015Prevalence of Latin-American-Mediterranean genetic family in population structure of Mycobacterium tuberculosis in Bulgaria.
1/2015The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru.
6/2014A study of Mycobacterium tuberculosis genotypic diversity & drug resistance mutations in Varanasi, north India.
1/2014Population structure among mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Colombia.
1/2014Predicting Mycobacterium tuberculosis complex clades using knowledge-based Bayesian networks.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nalin Rastogi Research Topics

Disease

30Tuberculosis (Tuberculoses)
06/2023 - 05/2002
2Coinfection
07/2015 - 06/2012
2Extensively Drug-Resistant Tuberculosis
01/2014 - 06/2013
2Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
11/2010 - 08/2008
1Ulcer
01/2015
1Reinfection
03/2011
1Infections
02/2003

Drug/Important Bio-Agent (IBA)

15lipoarabinomannan (LAM)IBA
12/2016 - 03/2005
6Rifampin (Rifampicin)FDA LinkGeneric
07/2015 - 05/2002
5DNA (Deoxyribonucleic Acid)IBA
06/2023 - 01/2003
5Isoniazid (Ftivazide)FDA LinkGeneric
06/2014 - 11/2010
3prostaglandin G2IBA
01/2012 - 08/2005
2Streptomycin (Streptomycin Sulfate)FDA Link
06/2014 - 01/2012
2Ethambutol (Myambutol)FDA LinkGeneric
06/2014 - 01/2012
2FluoroquinolonesIBA
06/2013 - 08/2008
2Nitrate ReductaseIBA
05/2010 - 08/2005
1carbamoylpyridoxal 5'-phosphate (CPLP)IBA
01/2019
1Indicators and Reagents (Reagents)IBA
01/2019
1Genetic Markers (Genetic Marker)IBA
12/2015
1OligonucleotidesIBA
01/2014
1Biomarkers (Surrogate Marker)IBA
01/2014
1KanamycinFDA Link
06/2013
1Amikacin (A.M.K)FDA LinkGeneric
06/2013
1Capreomycin (Capastat)FDA Link
06/2013
14- Acetamido- 4'- isothiocyanatostilbene- 2,2'- disulfonic Acid (SITS)IBA
06/2012
12'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA
03/2011
1Antitubercular AgentsIBA
10/2006
1RNA (Ribonucleic Acid)IBA
05/2002

Therapy/Procedure

1Injections
06/2013
1Therapeutics
02/2003